Form 483 has been a source of chronic pain for Indian pharma companies that have a major presence in the US. Issued by the US food and drug administration (USFDA), the form notifies a company of objectionable conditions found at its drug units. At the conclusion of an inspection, companies have to respond to the US regulator about their corrective action plan and then implement these plans expeditiously.
Fastest Growing Companies 2015
After a dream run, Sun Pharma is grappling with growth and regulatory issues. Can the country’s biggest drug maker rediscover its mojo?
Summer wine and salad
Kishore Singh - January 19, 2015
The million-dollar question: Is investing a game of luck or skill?
Shankar Sharma - May 04, 2021
Every crisis is an opportunity, if you are on the right side of equities
Samir Arora - May 04, 2021
Viraj Mehta trusts the toughness and bounce of a company that has seen many trials
Viraj Mehta - May 04, 2021
Safir Anand spots a mid-sized company with the right chemistry and catalytic circumstances
Safir Anand - May 07, 2021